Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia

Phase II Trial of Polyphenon E in Current and Former Smokers With Bronchial Dysplasia

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Polyphenon E, a substance found in green tea, may keep cancer from forming in current or former smokers with bronchial dysplasia.

PURPOSE: This randomized phase II trial is studying the side effects and how well green tea extract works in treating current or former smokers with bronchial dysplasia.

Study Overview

• Status: Terminated
• Conditions: Tobacco Use Disorder; Lung Cancer; Precancerous Condition
• Intervention / Treatment: Other: placebo; Drug: defined green tea catechin extract

Detailed Description

OBJECTIVES:

Primary

• To evaluate the efficacy and safety of Polyphenon E, a defined green tea catechin extract, in current or former smokers with bronchial dysplasia and increased inflammatory load as measured by C-reactive protein.

Secondary

• To evaluate the ability of Polyphenon E to modulate other surrogate endpoint biomarkers of oxidation stress, inflammation, aberrant methylation, cell cycle regulation, apoptosis, oncogene/tumor suppressor gene expression, as well as phase I and II enzyme regulation in biological samples from these patients.
• To establish a library of optical coherent tomography (OCT) images of the bronchial epithelium with corresponding histopathology, nuclear morphometry, and other biomarker information.
• To assess the potential of OCT as a non-biopsy method for evaluating chemoprevention agents.

OUTLINE: This is a multicenter study. Patients are stratified by gender. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.

Patients undergo standard white-light bronchoscopy and fluorescence bronchoscopy with optical coherence tomography (OCT) at baseline and at 3 months. During these procedures, patients are evaluated using the Onco-LIFE clinical device, which digitally records OCT images of abnormal areas or areas suspicious for intraepithelial neoplasia or invasive carcinoma. Once these areas have been localized, patients are biopsied under fluorescence bronchoscopy guidance to obtain both dysplastic bronchial epithelial tissue and normal bronchial mucosa. Biopsy specimens are examined by immunostaining for tissue-based biomarkers (i.e., Ki-67, cleaved caspase-3, p53, and VEGF). Patients also undergo oral brushing, bronchial brushing, and bronchoalveolar lavage at baseline and at 3 months to obtain bronchial epithelial cells for differential gene expression and methylation biomarker studies (e.g., cDNA microarray analysis, polymerase chain reaction, and northern blotting). Cytokines and other molecular biomarkers (i.e., C-reactive protein, surfactant protein D, oxidized glutathione, interleukin [IL]-6, IL-13, and macrophage inflammatory protein-1 levels) are measured in blood and bronchoalveolar lavage fluid samples by enzyme-linked immunoassay. Plasma EGCG levels are assessed by high-performance liquid chromatography. Urine cotinine levels and exhaled carbon monoxide levels are also assessed.

After completion of study therapy, patients are followed at 1 month.

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • British Columbia Cancer Agency - Vancouver Cancer Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 74 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Current or former smoker who has smoked ≥ 30 pack-years (i.e., 1 pack per day for ≥ 30 years)

  • A former smoker is defined as one who has stopped smoking for ≥ 1 year
• C-reactive protein level > 1.2 mg/L
• One or more areas of dysplasia with a surface diameter > 1.2 mm on autofluorescence bronchoscopy
• No carcinoma in situ or invasive cancer on bronchoscopy
• No abnormal spiral chest CT scan suspicious of lung cancer

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Willing to take Polyphenon E or placebo twice a day regularly
• Willing to undergo bronchoscopy and spiral chest CT scan
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Creatinine normal
• Bilirubin normal
• AST and ALT normal
• Alkaline phosphatase normal
• No chronic active hepatitis or liver cirrhosis
• No severe heart disease (e.g., unstable angina or chronic congestive heart failure)
• No ongoing gastric ulcer
• No acute bronchitis or pneumonia within the past month
• No known reaction to xylocaine, salbutamol, midazolam, or alfentanil
• No known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients
• No medical condition, such as acute or chronic respiratory failure or bleeding disorder, that, in the opinion of the investigator, could jeopardize patient safety during study participation

PRIOR CONCURRENT THERAPY:

• No concurrent consumption of > 7 cups of tea a week
• No other concurrent natural health products containing green tea compounds
• No concurrent antiarrhythmic agents
• No concurrent anticoagulants, such as warfarin or heparin

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm I; Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.	Drug: defined green tea catechin extract; Given orally
Placebo Comparator: Arm II; Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.	Other: placebo; Given orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in the severity of dysplasia (as defined by WHO criteria) in bronchial biopsy specimens as assessed at baseline and at 3 months	3 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in the morphometric index in bronchial biopsy specimens as assessed at baseline and at 3 months	3 months
Change in the concentrations (or grades) of Ki-67, p53, cleaved caspase-3, and VEGF in bronchial biopsy specimens as assessed by immunostaining at baseline and at 3 months	3 months
Methylation biomarkers in bronchoalveolar lavage (BAL) cells as assessed at baseline and at 3 months	3 months
Oncogene/ tumor suppressor gene expression in bronchial brush cells as assessed by cDNA microarray analysis at baseline and at 3 months	3 months
Phase I and II enzyme regulation in bronchial brush cells as assessed by Affymetrix microarray analysis at baseline and at 3 months	3 months
Change in C-reactive protein levels in plasma as assessed by enzyme-linked immunoassay (ELISA) at baseline and then monthly for 3 months	3 months
Volumetric measurement of CT-detected lung nodules at baseline and then every 3-12 months for up to 24 months, depending on the size of the nodule	24 months
Change in the concentrations (or grades) of surfactant protein D, oxidized glutathione, interleukin (IL)-6, IL-13, and MPIF-1 in plasma and BAL cells as assessed by ELISA at baseline and at 3 months	3 months

Collaborators and Investigators

• Sponsor: British Columbia Cancer Agency
• Collaborators: National Cancer Institute (NCI); University of Cincinnati

Study record dates

Study Major Dates

• Study Start: October 1, 2006
• Primary Completion (Actual): June 1, 2011
• Study Completion (Actual): July 1, 2011

Study Registration Dates

• First Submitted: February 8, 2008
• First Submitted That Met QC Criteria: February 8, 2008
• First Posted (Estimate): February 11, 2008

Study Record Updates

• Last Update Posted (Estimate): March 9, 2012
• Last Update Submitted That Met QC Criteria: March 7, 2012
• Last Verified: March 1, 2012

More Information

Terms related to this study

• Keywords: non-small cell lung cancer; tobacco use disorder; squamous lung dysplasia
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Neoplasms; Tobacco Use Disorder; Precancerous Conditions; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Neuroprotective Agents; Protective Agents; Antioxidants; Anticarcinogenic Agents; Antimutagenic Agents; Epigallocatechin gallate
• Other Study ID Numbers: CDR0000578224; P01CA096964 (U.S. NIH Grant/Contract); BCCA-H07-02401; H07-02401